New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
08:32 EDTPTXPernix Therapeutics agrees to divest Houston manufacturing operations
Pernix Therapeutics Holdings announced that it has signed a definitive agreement to divest its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC to Woodfield Pharmaceutical LLC. Woodfield will acquire the entire PML operation and will assume the mortgage associated with the facility. Pernix expects to receive approximately $1.2M in net proceeds at closing and realize approximately $5M in annualized cost savings from the divestiture. As part of the agreement, Woodfield will continue to manufacture the existing Pernix products under a long-term supply agreement. Pernix anticipates a closing of April 15. Closing of the transaction is subject to standard closing conditions and deliveries. In addition, closing on the sale of certain of the real estate assets may extend beyond the anticipated closing date.
News For PTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
07:41 EDTPTXPernix Therapeutics submits sNDA for TREXIMET use in adolescent patients
Subscribe for More Information
November 11, 2014
09:36 EDTPTXPernix Therapeutics initiated with an Outperform at Avondale
Target $20.
November 10, 2014
08:11 EDTPTXPernix Therapeutics sees FY15 revenue $230M, consensus $214.07M
Sees FY15 adjusted EBITDA $95M.
08:11 EDTPTXPernix Therapeutics backs FY14 revenue $110M-$120M, consensus $116.87M
Sees FY14 adjusted EBITDA $22M-$24M.
08:10 EDTPTXPernix Therapeutics reports Q3 adjusted EPS (2c), consensus 0c
Reports Q3 revenue $31.5M, consensus $28.13M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use